220 related articles for article (PubMed ID: 18589441)
1. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry.
Minkov M; Steiner M; Pötschger U; Aricò M; Braier J; Donadieu J; Grois N; Henter JI; Janka G; McClain K; Weitzman S; Windebank K; Ladisch S; Gadner H;
J Pediatr; 2008 Nov; 153(5):700-5, 705.e1-2. PubMed ID: 18589441
[TBL] [Abstract][Full Text] [Related]
2. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
[TBL] [Abstract][Full Text] [Related]
3. Reactivation and risk of sequelae in Langerhans cell histiocytosis.
Pollono D; Rey G; Latella A; Rosso D; Chantada G; Braier J
Pediatr Blood Cancer; 2007 Jun; 48(7):696-9. PubMed ID: 17252574
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for diabetes insipidus in langerhans cell histiocytosis.
Grois N; Pötschger U; Prosch H; Minkov M; Arico M; Braier J; Henter JI; Janka-Schaub G; Ladisch S; Ritter J; Steiner M; Unger E; Gadner H;
Pediatr Blood Cancer; 2006 Feb; 46(2):228-33. PubMed ID: 16047354
[TBL] [Abstract][Full Text] [Related]
5. Langerhans cell histiocytosis in neonates.
Minkov M; Prosch H; Steiner M; Grois N; Pötschger U; Kaatsch P; Janka-Schaub G; Gadner H
Pediatr Blood Cancer; 2005 Nov; 45(6):802-7. PubMed ID: 15770639
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis.
Gadner H; Grois N; Arico M; Broadbent V; Ceci A; Jakobson A; Komp D; Michaelis J; Nicholson S; Pötschger U; Pritchard J; Ladisch S;
J Pediatr; 2001 May; 138(5):728-34. PubMed ID: 11343051
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary Langerhans cell histiocytosis: a variable disease in childhood.
Odame I; Li P; Lau L; Doda W; Noseworthy M; Babyn P; Weitzman S
Pediatr Blood Cancer; 2006 Dec; 47(7):889-93. PubMed ID: 16276522
[TBL] [Abstract][Full Text] [Related]
8. Predictors of outcome in children with Langerhans cell histiocytosis.
Jubran RF; Marachelian A; Dorey F; Malogolowkin M
Pediatr Blood Cancer; 2005 Jul; 45(1):37-42. PubMed ID: 15768381
[TBL] [Abstract][Full Text] [Related]
9. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group.
Haupt R; Nanduri V; Calevo MG; Bernstrand C; Braier JL; Broadbent V; Rey G; McClain KL; Janka-Schaub G; Egeler RM
Pediatr Blood Cancer; 2004 May; 42(5):438-44. PubMed ID: 15049016
[TBL] [Abstract][Full Text] [Related]
10. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study.
Titgemeyer C; Grois N; Minkov M; Flucher-Wolfram B; Gatterer-Menz I; Gadner H
Med Pediatr Oncol; 2001 Aug; 37(2):108-14. PubMed ID: 11496348
[TBL] [Abstract][Full Text] [Related]
11. Skeletal Langerhans cell histiocytosis in children: permanent consequences and health-related quality of life in long-term survivors.
Lau LM; Stuurman K; Weitzman S
Pediatr Blood Cancer; 2008 Mar; 50(3):607-12. PubMed ID: 17973322
[TBL] [Abstract][Full Text] [Related]
12. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution.
Braier J; Chantada G; Rosso D; Bernaldez P; Amaral D; Latella A; Balancini B; Masautis A; Goldberg J
Pediatr Hematol Oncol; 1999; 16(5):377-85. PubMed ID: 10505313
[TBL] [Abstract][Full Text] [Related]
13. Analysis of loss of heterozygosity in single-system and multisystem Langerhans' cell histiocytosis.
Chikwava KR; Hunt JL; Mantha GS; Murphy JE; Jaffe R
Pediatr Dev Pathol; 2007; 10(1):18-24. PubMed ID: 17378622
[TBL] [Abstract][Full Text] [Related]
14. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
[No Abstract] [Full Text] [Related]
15. Central diabetes insipidus as presenting symptom of Langerhans cell histiocytosis.
Prosch H; Grois N; Prayer D; Waldhauser F; Steiner M; Minkov M; Gadner H
Pediatr Blood Cancer; 2004 Oct; 43(5):594-9. PubMed ID: 15382278
[TBL] [Abstract][Full Text] [Related]
16. [Langerhans cell histiocytosis in adult patients--a disease with many faces. Experience of a centre and an overview of the disease symptoms].
Adam Z; Pour L; Krejcí M; Neubauer J; Vanícek J; Vasků V; Hájek R
Vnitr Lek; 2008 Nov; 54(11):1063-80. PubMed ID: 19069680
[TBL] [Abstract][Full Text] [Related]
17. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
[TBL] [Abstract][Full Text] [Related]
18. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.
Tazi A; Lorillon G; Haroche J; Neel A; Dominique S; Aouba A; Bouaziz JD; de Margerie-Melon C; Bugnet E; Cottin V; Comont T; Lavigne C; Kahn JE; Donadieu J; Chevret S
Orphanet J Rare Dis; 2017 May; 12(1):95. PubMed ID: 28532436
[TBL] [Abstract][Full Text] [Related]
19. Nationwide survey of single-system single site Langerhans cell histiocytosis in Japan.
Morimoto A; Ishida Y; Suzuki N; Ohga S; Shioda Y; Okimoto Y; Kudo K; Ishii E;
Pediatr Blood Cancer; 2010 Jan; 54(1):98-102. PubMed ID: 19728332
[TBL] [Abstract][Full Text] [Related]
20. Endocrine involvement in pediatric-onset Langerhans' cell histiocytosis: a population-based study.
Donadieu J; Rolon MA; Thomas C; Brugieres L; Plantaz D; Emile JF; Frappaz D; David M; Brauner R; Genereau T; Debray D; Cabrol S; Barthez MA; Hoang-Xuan K; Polak M;
J Pediatr; 2004 Mar; 144(3):344-50. PubMed ID: 15001940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
